Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients
BACKGROUND: The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients to receive this antiviral agent are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral.
MATERIAL AND METHODS: Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist.
RESULTS: Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes.
CONCLUSIONS: Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Anales del sistema sanitario de Navarra - 46(2023), 3 vom: 26. Dez. |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Análisis de las interacciones de nirmatrelvir/ritonavir en pacientes ambulatorios en Atención primaria |
|---|
| Beteiligte Personen: |
Rodríguez Esquíroz, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7R9A5P7H32 |
|---|
| Anmerkungen: |
Date Completed 27.12.2023 Date Revised 26.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23938/ASSN.1056 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366376098 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366376098 | ||
| 003 | DE-627 | ||
| 005 | 20240126232058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.23938/ASSN.1056 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM366376098 | ||
| 035 | |a (NLM)38146944 | ||
| 035 | |a (PII)e1056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Rodríguez Esquíroz, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients |
| 246 | 3 | 3 | |a Análisis de las interacciones de nirmatrelvir/ritonavir en pacientes ambulatorios en Atención primaria |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2023 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients to receive this antiviral agent are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral | ||
| 520 | |a MATERIAL AND METHODS: Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist | ||
| 520 | |a RESULTS: Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes | ||
| 520 | |a CONCLUSIONS: Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sanz Álvarez, Lorea |e verfasserin |4 aut | |
| 700 | 1 | |a Marín Marín, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a García González, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Aldave Cobos, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Garjón Parra, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anales del sistema sanitario de Navarra |d 1997 |g 46(2023), 3 vom: 26. Dez. |w (DE-627)NLM09649705X |x 2340-3527 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:3 |g day:26 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23938/ASSN.1056 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 3 |b 26 |c 12 | ||